An open-label, single-arm, phase IV clinical study was designed to evaluate the efficacy of afatinib in the treatment of NRG1-fused locally advanced/metastatic NSCLC and explore the clinical factors that may predict the effectiveness of treatment (NCT04814056) [40]. Here, NRG1 is linked to non-small cell lung carcinoma.